^
BIOMARKER:
BRAF V600
i
Other names: BRAF, B-raf proto-oncogene, B-raf proto-oncogene, Serine/threonine kinase, V-Raf murine sarcoma viral oncogene homolog B, Serine/threonine-protein kinase B-Raf, Proto-oncogene B-Raf, BRAF1, RAFB1, B-raf proto-oncogene Serine/threonine-protein kinase, Murine sarcoma viral (V-Raf) oncogene homolog B1, B-raf serine/threonine-protein, 94 KDa B-raf protein, B-RAF1
Entrez ID:
Related biomarkers:
BRAF V600
Melanoma
vemurafenib + atezolizumab + cobimetinib
Sensitive
:
A1
BRAF V600
Melanoma
binimetinib + encorafenib
Sensitive
:
A1
BRAF V600
Melanoma
vemurafenib + cobimetinib
Sensitive
:
A1
BRAF V600
Melanoma
dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600
Melanoma
trametinib
Sensitive
:
A1
BRAF V600
Melanoma
vemurafenib
Sensitive
:
A1
BRAF V600
NSCLC
trametinib + dabrafenib
Sensitive
:
A1
BRAF V600
Cutaneous Melanoma
trametinib
Resistant
:
A2
BRAF V600
Cutaneous Melanoma
vemurafenib + atezolizumab + cobimetinib
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
vemurafenib + cobimetinib
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
binimetinib + encorafenib
Sensitive
:
A2
BRAF V600
Melanoma
BRAF inhibitor + MEK inhibitor
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
dabrafenib + SNR1611
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
nivolumab + ipilimumab
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
pembrolizumab + dabrafenib
Sensitive
:
A2
BRAF V600
Cutaneous Melanoma
pembrolizumab + trametinib
Sensitive
:
A2
BRAF V600
Melanoma
dabrafenib + SNR1611 + PDR001
Sensitive
:
B
BRAF V600
Melanoma
nivolumab + ipilimumab
Sensitive
:
B
BRAF V600
Melanoma
PD1 inhibitor
Sensitive
:
B
BRAF V600
Thyroid Gland Carcinoma
vemurafenib
Sensitive
:
C1
BRAF V600
Ocular Melanoma
vemurafenib
Sensitive
:
C1
BRAF V600
Ocular Melanoma
trametinib + dabrafenib
Sensitive
:
C1
BRAF V600
Multiple Myeloma
binimetinib + encorafenib
Sensitive
:
C1
VERI is free for non-commercial use, no login needed.
Content on this site is for research purposes only and is not intended  to be a substitute for medical advice.
For commercial access, including additional premium features, please contact us.
By using VERI, you are agreeing to our